In the process of drug development, there has been an exceptionally high attrition rate in oncological compounds
entering late phases of testing. This has seen a concurrent reduction in approved NCEs (new chemical entities)
reaching patients. Network pharmacology has become a valuable tool in understanding the fine details of drug-target interactions
as well as painting a more practical picture of phenotype relationships to patients and drugs. By utilizing all the
tools achieved through molecular medicine and combining it with high throughput data analysis, interactions and mechanisms
can be elucidated and treatments reasonably tailored to patients expressing specific phenotypes (or genotypes) of
disease, essentially reigning in the phenomenon of drug attrition.